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INTRODUCTION
When tooth extraction is performed for the management of
diseases or trauma, complete hemostasis should be achieved
in order to prevent infection at the extraction site and sutures
may be used to allow natural healing. After extraction, the bone
resolves and remodels itself due to the nature of the alveolar
bone. Tallgren et al.
1 observed alveolar bone loss for 25
years and reported that most bone loss occurred during the first
year after extraction and that the bone continues to resolve after-
wards at a slow rate. Therefore, bone graft is performed at the
extraction site or at the resolved alveolar ridge in order to pre-
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pare the site for an implant, to prevent bone loss for aesthet-
ic reasons, or to preserve the extraction socket.
2,3
In the treatment of periodontal defects, current practice
includes the use of alloplastic materials, such as β -Tricalcium
phosphate (β -TCP) and hydroxyapatite (HA), which are syn-
thetic osteoconductive materials. A recent systematic review
has also indicated that bone replacement grafts lead to significant
clinical improvements in periodontal osseous defects.
4 Although
β -TCP/HA does not form new connective tissue, it provides
not only a scaffold for new bone formation but also facilitates
the stabilization of blood clot.
5 As β -TCP is porous, it entraps
growth factors within its micropores, thereby prolonging
their activity.
6
BMP, a protein derived from a subgroup of the transforming
growth factor β family,
7 accelerates ossification by controlling
the essential factors of the bone induction cascade, resulting
in the proliferation of osteoblasts from mesenchymal stem cells
and the biosynthesis of bone matrices.
8,9 Recombinant human
BMPs are currently produced by BMP gene-transfected
mammalian cell (CHO) cultures,
10,11 and rhBMP-2 and BMP-
7 are commercially available for the treatment of bony
defects.
12,13 One of the problems associated with clinical
application of CHO-cell-derived rhBMP-2 (CrhBMP-2) is its
high costs due to high dose requirements. One possible way
of solving this problem is to produce monomer rhBMPs
from BMP-gene-transfected Escherichia coli (E. coli) with a
high efficiency and low costs. Bessho et al.
14 examined the bone-
inducing ability of an E. coli-derived rhBMP-2 (ErhBMP-2)
variant with an N-terminal sequence and compared it with
CrhBMP-2. Quantitative analysis indicated that the activity of
ErhBMP-2 is similar to that of CrhBMP-2. However, it is unclear
whether the characteristics of ErhBMP-2 are appropriate for
clinical application. In particular, there have been few studies
about the efficacy and safety of ErhBMP-2 and β -TCP graft
materials in osseous defects, such as tooth extraction sockets.
Recently, ErhBMP-2 has been developed in the Republic of
Korea. Therefore, this randomized clinical trial was con-
ducted to assess the safety and effectiveness of the ErhBMP-
2 in alveolar bone regeneration as well as preservation of the
β -TCP bone graft material that contains ErhBMP-2.
MATERIALS AND METHODS
Study design
A double-blind, active-controlled, randomized, parallel,
multicenter, prospective, phase III study was conducted with
the approval of the Korean Food and Drug Association at 3 cen-
ters in the Republic of Korea from April 2009 to March
2010, in order to assess the efficacy of ErhBMP-2 + β -
TCP/HA in comparison with β -TCP/HA alone for the treatment
of tooth extracted sockets. The Institutional Review Board at
each of the 3 study centers approved the study protocol. 
This study initially involved 72 patients aged from 35 to 65
years at the 3 study centers, whose premolars or molars were
indicated for extraction with less than 50% of localized alve-
olar vertical bone loss (Table 1). However, patients with the
following conditions were excluded from the study: (1) those
who had severe periodontitis with localized alveolar vertical
bone loss of more than 50%, (2) those who were currently preg-
nant or planned to get pregnant within 1 year of the experiment,
(3) those who were older than 65 years, (4) those who had recent
myocardial infarction or uncontrolled bleeding disorders, (5)
those who were contraindicated to minor surgeries, (6) those
who had mental illness or suspected mental illness or hyper-
sensitivity to bone graft materials, and (7) those who were clas-
sified as inappropriate for clinical trial participation by the clin-
ician due to ethical reasons or other possible impacts on the results
of clinical trials.
Patients were divided into 2 groups: the experiment group
who had ErhBMP-2 coated TCP/HA (Cowellmedi Co, Pusan,
Korea; 1.5 mg/ml) and the control group who had TCP/HA graft
material alone transplanted immediately into the socket of tooth
extraction. 
Study protocol
At the first visit, the purpose of the study was explained, writ-
ten consent was obtained, and patient blood samples were tak-
en to check pre-existing antibodies against ErhBMP-2. At the
second visit, the indicated tooth of the patients, who pro-
Table 1. Age and sex distribution of the control and experiment groups
Variable
Control Group Experiment Group  All
N = 36 N = 36 N = 72
Age Average ±SD 52.75 ±6.29 52.80 ±7.20 52.77 ±6.71
< 50   12 (33.33) 10 (27.78) 22 (30.56)
50 - 59 17 (47.22) 20 (55.56) 37 (51.39)
> 60 7 (19.44) 6 (16.67) 13 (18.06)
Sex Men 22 (61.11) 20 (55.56) 42 (58.33)
Number (%) Women 14 (38.89) 16 (44.44) 30 (41.67)163 J Adv Prosthodont 2011;3:161-5
vided written consent, was extracted and the socket was
filled with the bone graft and sutured. The first CT scan was
then taken to determine baseline characteristics. At the third
and fourth visits, sutures were removed and the patient’ s
intraoral condition was checked. The fifth visit was made 1 month
after the second visit, and a blood sample was drawn and an
intraoral examination was performed. The final visit was
made 3 months after the second visit, and a computed tomog-
raphy (CT) and an intraoral examination were performed.
Efficacy parameter
To verify the effectiveness of these bone grafts, CT was per-
formed before the transplantation and 3 months after the
transplantation and healing status was compared between
the two. The efficacy endpoints that were used to measure the
degree of bone induction included alveolar bone height (1 mea-
surement) and 3 measurements of bone width (1 measurement
each at 25%, 50% and 75% of the extraction socket length
[ESL]). This method followed a previous similar study.
15 In addi-
tion, maxillary teeth extraction sockets were measured by the
same way as in a previous study.
15 Mandibular tooth extraction
sockets were measured by the method depicted in Fig. 1.
Statistical analysis
In order to assess the major effects of the bone graft mate-
rials, alveolar bone heights at baseline and 3 months post-trans-
plantation were compared between the control and experiment
groups. The mean and standard deviation of the test parame-
Fig. 1. Computed tomography (CT) height and width mea-
surements at baseline before tooth extraction (A) and 3 months
after transplantation (B).
(1) Point awas marked on the same point of the lower edge of
the mandible on representative CT scans taken before and
after transplantation. (2) Points band cwere marked at the most
prominent points on the buccal and lingual aspects, respectively.
(3) Line A connected points band c. (4) Line B, the  “axial line” ,
connected the midpoint between points band c, which was called
(5) Line C was drawn perpendicular to the  “axial line” from the
most superior point of the alveolar bone. (6) Bone height was
defined as the distance between point dand line C. (7) The dis-
tance between point dand line C was divided into 4 aliquot por-
tions and bone width was measured on each line before and after
transplantation.
Fig. 2. Computed tomography views at baseline following tooth extraction (A, C) and 3 months post-treatment (B, D).
In the control group, there was resorption of the buccal plate and reduction in bone width. However, in the experimental group, the buccal plate was
maintained and bone width increased (white arrow). ((A) at post-treatment following tooth extraction in the control group, (B) after 3 months in the
control group (C) at post-treatment following tooth extraction in the experiment group, (D) after 3 months in the experiment group).
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ters were calculated using SPSS (Ver. 12.0, SPSS, Chicago, IL,
USA). The paired t test was used to determine the significance
of the changes. To assess the minor effects of the bone graft
materials, changes in alveolar bone width at 25% ESL, 50%
ESL and 75% ESL at the baseline and 3 months post-treatment
were compared between control and experiment groups. The
paired t test was used to determine the significance of the changes.
A P value of <.05 was considered statistically significant.
RESULTS
Changes in alveolar bone height were examined using CT scans
taken before and 3 months after treatment, which turned out
to be -1.087±1.413 mm in the control group and -0.059±0.960
mm in the experimental group. The paired Student t test was
used to compare the mean change between the 2 groups in alve-
olar bone height preservation, and the difference was statistically
significant (P<.01) (Table 2). Changes in alveolar bone width
were also measured to determine the minor effects of bone grafts
on the preservation of alveolar bone. At 25% ESL, the
changes were 0.006±1.149 mm in the control group and
1.279±1.387 mm in the experimental group. At 50% ESL, the
changes were 0.542±1.157 mm and 1.239±1.249 mm,
respectively, and at 75% ESL, the changes were 1.405±
1.753 mm and 1.863±2.310 mm, respectively. The paired
Student t-test was used to compare the changes between the
2 groups, and the differences were statistically significant
(P<.01 for 25% ESL, and P<.05 for 50% ESL) (Table 3).
DISCUSSION
The potential therapeutic efficacy of rhBMP-2 in orthope-
dic and craniofacial reconstruction has been investigated.
Preclinical studies have evaluated induction and repair of
bony defects in a variety of indications.
16,17 A previous study
of utilizing rhBMP-2 in humans showed the safety and tech-
nical feasibility. Howell et al.
18 reported that in local ridge preser-
vation and augmentation, 0.43 mg/ml rhBMP/absorbable
collagen sponge (ACS) was well tolerated locally and sys-
temically, with no adverse events. In a pivotal study by
Fiorellini et al.
15 assessment of alveolar bone indicated that
patients treated with 1.50 mg/ml CrhBMP-2/ACS had sig-
nificantly better results after bone augmentation than control
patients (P≤.05). The adequacy of bone for the placement of
a dental implant was approximately twice greater in the
rhBMP-2/ACS group than in the non-treatment or placebo group. 
This randomized and double-blind clinical trial was designed
to assess the safety and bone regenerative ability of the
ErhBMP-2 coated β -TCP/HA bone graft material, which is coat-
ed with ErhBMP-2. After the completion of the clinical trial,
the ANOVA test was performed to evaluate whether the
evaluation parameters had homogeneity according to institutional
and demographic data. Since there were no significant variations
in these parameters, the results of this study on the safety and
effectiveness of the bone graft materials are considered valid. 
In this study, to assess the major effects of the bone graft mate-
rial in preserving the alveolar bone, alveolar bone height at base-
line and 3 months post-treatment were compared by measuring
bone height in the cross sectional CT images. To assess the minor
effects of the bone graft material, changes in alveolar bone width
at 25% ESL, 50% ESL and 75% ESL were compared using
cross-sectional CT images at baseline and 3 months post-treat-
ment. In addition, clinical observation was performed to
evaluate the safety of the graft material, and antibody against
rhBMP-2 was tested to evaluate its immunological safety. No
clinical adverse reactions or even inflammatory responses were
observed in patients who received the bone graft. Basedon the
immunological evaluations of the blood tests at the fifth vis-
Table 3. Evaluation of the efficacy in maintaining alveolar bone width 




Bone width at 75% ESL Control 1.405 1.753 (0.812, 1.998) -0.95 
Experiment 1.863 2.310 (1.081, 2.644) (.346)
At 50% ESL Control 0.542 1.157 (0.15, 0.934) -2.46* 
Experiment 1.239 1.249 (0.816, 1.662) (.016)
At 25% ESL Control 0.006 1.149 (-0.383, 0.395) -4.24** 
Experiment 1.279 1.387 (0.81, 1.749) (<.0001)
ESL: Extraction Socket Level
*: P<.05, **: P<.01, 
�: Student t-test
Table 2. Evaluation of the efficacy in maintaining alveolar bone height
Group Average SD 95% CI P value
�
ESL
Control -1.087 1.413 (-1.565, -0.609) -3.61**
Experiment -0.059 0.960 (-0.384, 0.266) -0.0006
ESL: extraction socket level
*: P<.05, **: P<.01, 
�: Student t-test
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it of 72 patients (36 in the control group and 36 in the exper-
iment group), none of the patients were suspected of having
developed antibodies against the bone graft material. CT
images were analyzed using the same software (Ondemend,
Cybermed Inc, LA, CA, USA) at the same site immediately after
transplantation and 3 months post-transplantation. 
Changes in alveolar bone height were considered as a major
evaluation variable in determining the effectiveness of the bone
graft for alveolar bone regeneration. Based on CT scans at base-
line and 3 months post-transplantation, the changing rate of the
alveolar bone height, was higher in the control group than in
the experimental group (P<.05). Changes in alveolar bone width
were considered a minor evaluation variable in determining the
effectiveness of the bone graft in alveolar bone regeneration. 
In this study, materials other than the subject’ s gingiva
(e.g., collagen membrane and others) were excluded in order
to eliminate the effects of other factors. However, one crucial
factor that affects the outcome of the conventional guided-bone
regeneration (GBR) procedure is the fact that the treatment area
must be protected from the surrounding soft tissue. Therefore,
because of chewing, brushing and other oral habits, as well as
differences in remaining gingival levels, the tested bone graft
material did not survive at the treatment site over a sufficient
time period. Therefore, it is conceivable that if the bone
graft material is transplanted after allowing the gingival tissue
to heal to a certain extent after the extraction, rather than being
transplanted immediately after extraction, the alveolar bone preser-
vation effect of the bone graft material may increase.
CONCLUSION
In this study, β -TCP/HA bone grafts coated with ErhBMP-
2 were found to be more effective in preserving alveolar
bone than conventional β -TCP/HA alloplastic bone grafts.
Furthermore, during the experiment, no adverse reactions to
the graft material were observed. Thus, this alloplastic bone
graft coated with ErhBMP-2 is considered to be an effective
bone graft material. 
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